IL13RA2 and glioblastoma: Currently, phase I studies combining anti-EGFRvIII CAR-T cells with pembrolizumab (NCT03726515) and anti-IL-13Rα2 CAR-T cells with or without ipilimumab and nivolumab (NCT04003649) are now recruiting patients with glioblastoma.